Falko Tesch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Falko Tesch has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Jochen Schmitt
Center for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
18 shared publications Martin Seifert
Center for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus at TUD Dresden University of Technology, Dresden, Germany
12 shared publicationsClaudia Schulte
BARMER Institut für Gesundheitssystemforschung (bifg), Berlin, Germany
9 shared publicationsCordula Riederer
DAK-Gesundheit, Hamburg, Germany
9 shared publicationsFriedrich Loser
Techniker Krankenkasse, Hamburg, Germany
9 shared publications- Martin Kolditz
Medical Department I, Division of Pneumology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
9 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by Springer Nature in Infection
- Vol. 54 (4) , 2115-2119
The role of cancer and immunosuppression in pneumocystis pneumonia: a large comprehensive population-based study
Although pneumocystis jirovecii pneumonia (PJP) in non-HIV patients is increasingly recognized, comprehensive data on immunosuppressive drivers remain limited. We conducted a population-based cohort study using a German health insurance’s claims data (2015–2023). PJP, comorbidities, immunocompromising conditions and therapies were identified by means of ICD-10-GM-, ATC- and OPS-coded records. 922,200 individuals were assessed for PJP occurrence, hospitalization and 30-day all-cause mortality. An Andersen-Gill model adjusted for key covariates. We identified 171 PJP episodes, with hospitalization in 88.3% and mortality in 24.5%. Frequent immunocompromising causes were hematologic cancers (42.6%), immunosuppressants (28.7%) and steroids (28.7%). Immunosuppression rather than typical CAP risk factors strongly predicted all outcomes (HR 49.9 [31.5–78.9]). Robust associations with PJP occurred for HIV (HR 67.5 [19.4–235]), systemic steroids (> 20 mg prednisone daily equivalent (HR 26.2 [13.2–52.1])) and hematologic cancers (HR 8.5 [4.5–16.3]). Mortality was driven by hematologic cancers (HR 13.9 [4.8–40.2]) and high-dose steroids (HR 8.6 [1.6–47.1]). Malignancy-related immunosuppression and steroids critically affect PJP risk and prognosis.
- 6 May 2026
- Published by Springer Nature in Infection
- Vol. 54 (4) , 2115-2119
Open AccessThe role of cancer and immunosuppression in pneumocystis pneumonia: a large comprehensive population-based study
Although pneumocystis jirovecii pneumonia (PJP) in non-HIV patients is increasingly recognized, comprehensive data on immunosuppressive drivers remain limited. We conducted a population-based cohort study using a German health insurance’s claims data (2015–2023). PJP, comorbidities, immunocompromising conditions and therapies were identified by means of ICD-10-GM-, ATC- and OPS-coded records. 922,200 individuals were assessed for PJP occurrence, hospitalization and 30-day all-cause mortality. An Andersen-Gill model adjusted for key covariates. We identified 171 PJP episodes, with hospitalization in 88.3% and mortality in 24.5%. Frequent immunocompromising causes were hematologic cancers (42.6%), immunosuppressants (28.7%) and steroids (28.7%). Immunosuppression rather than typical CAP risk factors strongly predicted all outcomes (HR 49.9 [31.5–78.9]). Robust associations with PJP occurred for HIV (HR 67.5 [19.4–235]), systemic steroids (> 20 mg prednisone daily equivalent (HR 26.2 [13.2–52.1])) and hematologic cancers (HR 8.5 [4.5–16.3]). Mortality was driven by hematologic cancers (HR 13.9 [4.8–40.2]) and high-dose steroids (HR 8.6 [1.6–47.1]). Malignancy-related immunosuppression and steroids critically affect PJP risk and prognosis.
- Open Access
- 22 April 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 138, 60-68
Burden and risk factors for 30-day readmission and mortality after CAP hospitalization: A population-based cohort study
- 22 April 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 138, 60-68
Open AccessBurden and risk factors for 30-day readmission and mortality after CAP hospitalization: A population-based cohort study
- Open Access
- 9 October 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-13
Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent
Background: Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as influenza. Methods: We investigated a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last influenza outbreak in 2018 and followed them up to 18 months. Results: We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the influenza or contemporary control cohort. The persistence of post-viral symptoms was similar between COVID-19 and influenza. Conclusion: Post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.
- 9 October 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-13
Open AccessPost-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent
Background: Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as influenza. Methods: We investigated a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last influenza outbreak in 2018 and followed them up to 18 months. Results: We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the influenza or contemporary control cohort. The persistence of post-viral symptoms was similar between COVID-19 and influenza. Conclusion: Post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.
- Open Access
- 16 September 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 415-426
Long/post-COVID in children and adolescents: symptom onset and recovery after one year based on healthcare records in Germany
Purpose: Evidence on the incidence and persistence of post-acute sequelae of COVID-19 (PASC) among children and adolescents is still limited. Methods: In this retrospective cohort study, 59,339 children and adolescents with laboratory-confirmed COVID-19 in 2020 and 170,940 matched controls were followed until 2021-09-30 using German routine healthcare data. Incidence rate differences (ΔIR) and ratios (IRR) of 96 potential PASC were estimated using Poisson regression. Analyses were stratified according to age (0–11, 12–17 years), and sex. At the individual level, persistence of diagnoses in patients with onset symptoms was tracked starting from the first quarter post-infection. Results: At 0–3 month follow-up, children and adolescents with a previous SARS-CoV-2 infection showed a 34% increased risk of adverse health outcome, and approximately 6% suffered from PASC in association with COVID-19. The attributable risk was higher among adolescents (≥ 12 years) than among children. For most common symptoms, IRRs largely persisted at 9–12 month follow-up. IRR were highest for rare conditions strongly associated with COVID-19, particularly inflammatory conditions among children 0–11 years, and chronic fatigue and respiratory insufficiency among adolescents. Tracking of diagnoses at the individual level revealed similar rates in the decline of symptoms among COVID-19 and control cohorts, generally leaving less than 10% of the patients with persistent diagnoses after 12 months. Conclusion: Although very few patients presented symptoms for longer than 12 months, excess morbidity among children and, particularly, adolescents with a history of COVID-19 means a relevant burden for pediatric care.
- 16 September 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 415-426
Open AccessLong/post-COVID in children and adolescents: symptom onset and recovery after one year based on healthcare records in Germany
Purpose: Evidence on the incidence and persistence of post-acute sequelae of COVID-19 (PASC) among children and adolescents is still limited. Methods: In this retrospective cohort study, 59,339 children and adolescents with laboratory-confirmed COVID-19 in 2020 and 170,940 matched controls were followed until 2021-09-30 using German routine healthcare data. Incidence rate differences (ΔIR) and ratios (IRR) of 96 potential PASC were estimated using Poisson regression. Analyses were stratified according to age (0–11, 12–17 years), and sex. At the individual level, persistence of diagnoses in patients with onset symptoms was tracked starting from the first quarter post-infection. Results: At 0–3 month follow-up, children and adolescents with a previous SARS-CoV-2 infection showed a 34% increased risk of adverse health outcome, and approximately 6% suffered from PASC in association with COVID-19. The attributable risk was higher among adolescents (≥ 12 years) than among children. For most common symptoms, IRRs largely persisted at 9–12 month follow-up. IRR were highest for rare conditions strongly associated with COVID-19, particularly inflammatory conditions among children 0–11 years, and chronic fatigue and respiratory insufficiency among adolescents. Tracking of diagnoses at the individual level revealed similar rates in the decline of symptoms among COVID-19 and control cohorts, generally leaving less than 10% of the patients with persistent diagnoses after 12 months. Conclusion: Although very few patients presented symptoms for longer than 12 months, excess morbidity among children and, particularly, adolescents with a history of COVID-19 means a relevant burden for pediatric care.
- Open Access
- 27 June 2024
- Published by Springer Nature in Infection
- Vol. 52 (6) , 2475-2486
Epidemiology and risk factors of community-acquired pneumonia in patients with different causes of immunosuppression
Immunosuppression constitutes a significant risk for community-acquired pneumonia (CAP). Nevertheless, specific causes of immunosuppression and their relevance for incidence, etiology and prognosis of CAP are insufficiently investigated.We conducted a population-based cohort study within a statutory health insurance in Germany from 2015 to 2018. CAP was retrieved by ICD-10-GM codes. Episodes of immunosuppression were identified by coded conditions (hematologic neoplasms, stem cell or organ transplantation, neutropenia, HIV, primary immunosuppressive syndromes) or treatments (immunosuppressants, antineoplastic drugs, systemic steroids). Endpoints were defined as occurrence of CAP (primary), hospitalization, 30-day mortality and CAP associated with rare pathogens. Our analysis utilized the Andersen-Gill model adjusted for sex, age, level of long-term care, vaccination status, community type and comorbidities.942,008 individuals with 54,781 CAPs were included (hospitalization 55%, 30-day mortality 14.5%). 6% of individuals showed at least one episode of immunosuppression during the study period with systemic steroids (39.8%) and hematologic neoplasms (26.7%) being most common. Immunosuppression was recorded in 7.7% of CAPs. Besides classical risk factors such as age and level of long-term care, immunosuppressed patients were most prone to CAP (HR 2.4[2.3–2.5]) and consecutive death (HR 1.9[1.8–2.1]). Organ and stem cell transplantation (HR 3.2[2.6–4.0] and 2.8[2.1–3.7], respectively), HIV (HR 3.2[1.9–5.4]) and systemic steroids (> 20 mg prednisone daily dose equivalent (HR 2.7[2.4–3.1])) showed the highest risk for contracting CAP. CAP by rare pathogens was strongly associated with immunosuppression (HR 17.1[12.0–24.5]), especially HIV (HR 34.1[7.6–153]) and systemic steroids (HR 8.2[4.6–14.8]).Our study elucidates the relevance of particular immunosuppressive conditions including systemic steroids for occurrence and prognosis of CAP.
- 27 June 2024
- Published by Springer Nature in Infection
- Vol. 52 (6) , 2475-2486
Open AccessEpidemiology and risk factors of community-acquired pneumonia in patients with different causes of immunosuppression
Immunosuppression constitutes a significant risk for community-acquired pneumonia (CAP). Nevertheless, specific causes of immunosuppression and their relevance for incidence, etiology and prognosis of CAP are insufficiently investigated.We conducted a population-based cohort study within a statutory health insurance in Germany from 2015 to 2018. CAP was retrieved by ICD-10-GM codes. Episodes of immunosuppression were identified by coded conditions (hematologic neoplasms, stem cell or organ transplantation, neutropenia, HIV, primary immunosuppressive syndromes) or treatments (immunosuppressants, antineoplastic drugs, systemic steroids). Endpoints were defined as occurrence of CAP (primary), hospitalization, 30-day mortality and CAP associated with rare pathogens. Our analysis utilized the Andersen-Gill model adjusted for sex, age, level of long-term care, vaccination status, community type and comorbidities.942,008 individuals with 54,781 CAPs were included (hospitalization 55%, 30-day mortality 14.5%). 6% of individuals showed at least one episode of immunosuppression during the study period with systemic steroids (39.8%) and hematologic neoplasms (26.7%) being most common. Immunosuppression was recorded in 7.7% of CAPs. Besides classical risk factors such as age and level of long-term care, immunosuppressed patients were most prone to CAP (HR 2.4[2.3–2.5]) and consecutive death (HR 1.9[1.8–2.1]). Organ and stem cell transplantation (HR 3.2[2.6–4.0] and 2.8[2.1–3.7], respectively), HIV (HR 3.2[1.9–5.4]) and systemic steroids (> 20 mg prednisone daily dose equivalent (HR 2.7[2.4–3.1])) showed the highest risk for contracting CAP. CAP by rare pathogens was strongly associated with immunosuppression (HR 17.1[12.0–24.5]), especially HIV (HR 34.1[7.6–153]) and systemic steroids (HR 8.2[4.6–14.8]).Our study elucidates the relevance of particular immunosuppressive conditions including systemic steroids for occurrence and prognosis of CAP.
- Open Access
- 6 February 2024
- Published by Springer Nature in Research Square
Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent
Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as Influenza. We addressed this topic by investigating a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last Influenza outbreak in 2018 and followed them up to 18 months. We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the Influenza cohort. Persistence of post-viral symptoms was however similar between COVID-19 and Influenza. We conclude that post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.
- 6 February 2024
- Published by Springer Nature in Research Square
Open AccessPost-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent
Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as Influenza. We addressed this topic by investigating a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last Influenza outbreak in 2018 and followed them up to 18 months. We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the Influenza cohort. Persistence of post-viral symptoms was however similar between COVID-19 and Influenza. We conclude that post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.
- 13 December 2023
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 77 (12) , 1029
Inzidenz und Risiko der ambulant erworbenen Pneumonie bei immunsupprimierten Patienten
Einleitung Immunsuppression (IS) ist ein wichtiger Risikofaktor für ambulant erworbene Pneumonien (CAP). Jedoch ist die Relevanz verschiedener Ursachen der IS für Inzidenz, Ätiologie und Prognose der CAP wenig untersucht. Methoden Im Studienzeitraum 2015-2018 erfolgte die retrospektive Kohortenstudie aller erwachsenen 2010-2018 durchgängig Versicherten der AOK PLUS aus Sachsen (>50 % der Landesbevölkerung). CAP und CAP mit Nachweis seltener Erreger wurden via ICD-10 Kodierung definiert; ambulante Fälle über Antiinfektivaverordnungen validiert. Episoden einer IS wurden über kodierte Konditionen (hämatologische Neoplasie, Stammzell- oder Organtransplantation, Neutropenie, HIV-Infektion, primäre IS-Syndrome) oder Therapien (Immunsuppressiva, Antineoplastika, systemische Steroidtherapie inkl. Dosis) identifiziert. Endpunkte waren Inzidenz, Hospitalisierung, 30-Tages-Letalität sowie kodierte seltene Erreger der CAP. Die Analyse erfolgte mittels multipler Regression (Anderson-Gill und Cox) unter Kontrolle weiterer Risikofaktoren (Alter, Geschlecht, Komorbiditäten, Impfungen, Pflegestatus, Wohnsitz) und der Ausweisung von Hazard Ratios (HR). Ergebnisse Wir untersuchten 942.008 Versicherte und 54.781 CAPs (Hospitalisierungsrate 55 %, 30-Tages-Letalität 14,5 %). 6 % der Versicherten wiesen mindestens eine Episode einer IS auf. Systemische Steroidtherapien (45 %), Hämatologische Neoplasien (27 %), Onkologika (24 %) und Immunsuppressiva (23 %) waren die häufigsten Gründe. 7,7 % aller CAPs traten unter IS auf. Nebst Alter, Pflegestatus und Komorbiditäten war IS wichtigster Risikofaktor für CAP (HR 2,4 [95%KI 2,4-2,5]) und CAP-assoziierte Letalität (HR 1,6 [1,4-1,8]). Innerhalb der IS wiesen Organtransplantation (HR 3,2 [2,6-4,0]), HIV (HR 3,2 [1,9-5,5]), systemische Steroide >20mg/d Prednisolonäquivalent (HR 2,7 [2,4-3,1]) und Immunsuppressiva (HR 1,5 [1,3-1,6]) das höchste Risiko auf. Für CAP durch seltene Erreger wie Aspergillus oder Pneumocystis war IS wichtigster Risikofaktor (HR 11,5 [8,1-16,4]). Besonders eine HIV-Infektion (HR 54 [20-146]) oder Steroidtherapie (HR 12,5 [7,8-20,1]) steigerten das Risiko. Diskussion Unsere Studie belegt Häufigkeit und Relevanz einzelner IS-assoziierter Konditionen; insbesondere einer hochdosierten Steroidtherapie für Risiko und Letalität einer CAP. Article published online: 13 December 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 13 December 2023
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 77 (12) , 1029
Inzidenz und Risiko der ambulant erworbenen Pneumonie bei immunsupprimierten Patienten
Einleitung Immunsuppression (IS) ist ein wichtiger Risikofaktor für ambulant erworbene Pneumonien (CAP). Jedoch ist die Relevanz verschiedener Ursachen der IS für Inzidenz, Ätiologie und Prognose der CAP wenig untersucht. Methoden Im Studienzeitraum 2015-2018 erfolgte die retrospektive Kohortenstudie aller erwachsenen 2010-2018 durchgängig Versicherten der AOK PLUS aus Sachsen (>50 % der Landesbevölkerung). CAP und CAP mit Nachweis seltener Erreger wurden via ICD-10 Kodierung definiert; ambulante Fälle über Antiinfektivaverordnungen validiert. Episoden einer IS wurden über kodierte Konditionen (hämatologische Neoplasie, Stammzell- oder Organtransplantation, Neutropenie, HIV-Infektion, primäre IS-Syndrome) oder Therapien (Immunsuppressiva, Antineoplastika, systemische Steroidtherapie inkl. Dosis) identifiziert. Endpunkte waren Inzidenz, Hospitalisierung, 30-Tages-Letalität sowie kodierte seltene Erreger der CAP. Die Analyse erfolgte mittels multipler Regression (Anderson-Gill und Cox) unter Kontrolle weiterer Risikofaktoren (Alter, Geschlecht, Komorbiditäten, Impfungen, Pflegestatus, Wohnsitz) und der Ausweisung von Hazard Ratios (HR). Ergebnisse Wir untersuchten 942.008 Versicherte und 54.781 CAPs (Hospitalisierungsrate 55 %, 30-Tages-Letalität 14,5 %). 6 % der Versicherten wiesen mindestens eine Episode einer IS auf. Systemische Steroidtherapien (45 %), Hämatologische Neoplasien (27 %), Onkologika (24 %) und Immunsuppressiva (23 %) waren die häufigsten Gründe. 7,7 % aller CAPs traten unter IS auf. Nebst Alter, Pflegestatus und Komorbiditäten war IS wichtigster Risikofaktor für CAP (HR 2,4 [95%KI 2,4-2,5]) und CAP-assoziierte Letalität (HR 1,6 [1,4-1,8]). Innerhalb der IS wiesen Organtransplantation (HR 3,2 [2,6-4,0]), HIV (HR 3,2 [1,9-5,5]), systemische Steroide >20mg/d Prednisolonäquivalent (HR 2,7 [2,4-3,1]) und Immunsuppressiva (HR 1,5 [1,3-1,6]) das höchste Risiko auf. Für CAP durch seltene Erreger wie Aspergillus oder Pneumocystis war IS wichtigster Risikofaktor (HR 11,5 [8,1-16,4]). Besonders eine HIV-Infektion (HR 54 [20-146]) oder Steroidtherapie (HR 12,5 [7,8-20,1]) steigerten das Risiko. Diskussion Unsere Studie belegt Häufigkeit und Relevanz einzelner IS-assoziierter Konditionen; insbesondere einer hochdosierten Steroidtherapie für Risiko und Letalität einer CAP. Article published online: 13 December 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 2 October 2023
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 24 (1) , 1-9
Socioeconomic differences in the utilization of diagnostic imaging and non-pharmaceutical conservative therapies for spinal diseases
Background: A different utilization of health care services due to socioeconomic status on the same health plan contradicts the principle of equal treatment. We investigated the presence and magnitude of socioeconomic differences in utilization of diagnostic imaging and non-pharmaceutical conservative therapies for patients with spinal diseases. Methods: The cohort study based on routine healthcare data from Germany with 11.7 million patient-years between 2012 and 2016 for patients with physician-confirmed spinal diseases (ICD-10: M40-M54), occupation and age 20 to 64 years. A Poisson model estimated the effects of the socioeconomic status (school education, professional education and occupational position) for the risk ratio of receiving diagnostic imaging (radiography, computed tomography, magnetic resonance imaging) and non-pharmaceutical conservative therapies (physical therapy including exercise therapy, manual therapy and massage, spinal manipulative therapy, acupuncture). Results: Patients received diagnostic imaging in 26%, physical therapy in 32%, spinal manipulative therapy in 25%, and acupuncture in 4% of all patient-years. Similar to previous survey-based studies higher rates of utilization were associated with higher socioeconomic status. These differences were most pronounced for manual therapy, exercise therapy, and magnetic resonance imaging. Conclusions: The observed differences in health care utilization were highly related to socioeconomic status. Socioeconomic differences were higher for more expensive health services. Further research is necessary to identify barriers to equitable access to health services and to take appropriate action to decrease existing social disparities.
- 2 October 2023
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 24 (1) , 1-9
Open AccessSocioeconomic differences in the utilization of diagnostic imaging and non-pharmaceutical conservative therapies for spinal diseases
Background: A different utilization of health care services due to socioeconomic status on the same health plan contradicts the principle of equal treatment. We investigated the presence and magnitude of socioeconomic differences in utilization of diagnostic imaging and non-pharmaceutical conservative therapies for patients with spinal diseases. Methods: The cohort study based on routine healthcare data from Germany with 11.7 million patient-years between 2012 and 2016 for patients with physician-confirmed spinal diseases (ICD-10: M40-M54), occupation and age 20 to 64 years. A Poisson model estimated the effects of the socioeconomic status (school education, professional education and occupational position) for the risk ratio of receiving diagnostic imaging (radiography, computed tomography, magnetic resonance imaging) and non-pharmaceutical conservative therapies (physical therapy including exercise therapy, manual therapy and massage, spinal manipulative therapy, acupuncture). Results: Patients received diagnostic imaging in 26%, physical therapy in 32%, spinal manipulative therapy in 25%, and acupuncture in 4% of all patient-years. Similar to previous survey-based studies higher rates of utilization were associated with higher socioeconomic status. These differences were most pronounced for manual therapy, exercise therapy, and magnetic resonance imaging. Conclusions: The observed differences in health care utilization were highly related to socioeconomic status. Socioeconomic differences were higher for more expensive health services. Further research is necessary to identify barriers to equitable access to health services and to take appropriate action to decrease existing social disparities.
- Open Access
- 4 August 2023
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 23 (1) , 1-9
Acceptance of a digital therapy recommender system for psoriasis
Background: About 2% of the German population are affected by psoriasis. A growing number of cost-intensive systemic treatments are available. Surveys have shown high proportions of patients with moderate to severe psoriasis are not adequately treated despite a high disease burden. Digital therapy recommendation systems (TRS) may help implement guideline-based treatment. However, little is known about the acceptance of such clinical decision support systems (CDSSs). Therefore, the aim of the study was to access the acceptance of a prototypical TRS demonstrator. Methods: Three scenarios (potential test patients with psoriasis but different sociodemographic and clinical characteristics, previous treatments, desire to have children, and multiple comorbidities) were designed in the demonstrator. The TRS demonstrator and test patients were presented to a random sample of 76 dermatologists attending a national dermatology conference in a cross-sectional face-to-face survey with case vignettes. The dermatologist were asked to rate the demonstrator by system usability scale (SUS), whether they would use it for certain patients populations and barriers of usage. Reasons for potential usage of the TRS demonstrator were tested via a Poisson regression with robust standard errors. Results: Acceptance of the TRS was highest for patients eligible for systemic therapy (82%). 50% of participants accepted the system for patients with additional comorbidities and 43% for patients with special subtypes of psoriasis. Dermatologists in the outpatient sector or with many patients per week were less willing to use the TRS for patients with special psoriasis-subtypes. Dermatologists rated the demonstrator as acceptable with an mean SUS of 76.8. Participants whose SUS was 10 points above average were 27% more likely to use TRS for special psoriasis-subtypes. The main barrier in using the TRS was time demand (47.4%). Participants who perceived time as an obstacle were 22.3% less willing to use TRS with systemic therapy patients. 27.6% of physicians stated that they did not understand exactly how the recommendation was generated by the TRS, with no effect on the preparedness to use the system. Conclusion: The considerably high acceptance and the preparedness to use the psoriasis CDSS suggests that a TRS appears to be implementable in routine healthcare and may improve clinical care. Main barrier is the additional time demand posed on dermatologists in a busy clinical setting. Therefore, it will be a major challenge to identify a limited set of variables that still allows a valid recommendation with precise prediction of the patient-individual benefits and harms.
- 4 August 2023
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 23 (1) , 1-9
Open AccessAcceptance of a digital therapy recommender system for psoriasis
Background: About 2% of the German population are affected by psoriasis. A growing number of cost-intensive systemic treatments are available. Surveys have shown high proportions of patients with moderate to severe psoriasis are not adequately treated despite a high disease burden. Digital therapy recommendation systems (TRS) may help implement guideline-based treatment. However, little is known about the acceptance of such clinical decision support systems (CDSSs). Therefore, the aim of the study was to access the acceptance of a prototypical TRS demonstrator. Methods: Three scenarios (potential test patients with psoriasis but different sociodemographic and clinical characteristics, previous treatments, desire to have children, and multiple comorbidities) were designed in the demonstrator. The TRS demonstrator and test patients were presented to a random sample of 76 dermatologists attending a national dermatology conference in a cross-sectional face-to-face survey with case vignettes. The dermatologist were asked to rate the demonstrator by system usability scale (SUS), whether they would use it for certain patients populations and barriers of usage. Reasons for potential usage of the TRS demonstrator were tested via a Poisson regression with robust standard errors. Results: Acceptance of the TRS was highest for patients eligible for systemic therapy (82%). 50% of participants accepted the system for patients with additional comorbidities and 43% for patients with special subtypes of psoriasis. Dermatologists in the outpatient sector or with many patients per week were less willing to use the TRS for patients with special psoriasis-subtypes. Dermatologists rated the demonstrator as acceptable with an mean SUS of 76.8. Participants whose SUS was 10 points above average were 27% more likely to use TRS for special psoriasis-subtypes. The main barrier in using the TRS was time demand (47.4%). Participants who perceived time as an obstacle were 22.3% less willing to use TRS with systemic therapy patients. 27.6% of physicians stated that they did not understand exactly how the recommendation was generated by the TRS, with no effect on the preparedness to use the system. Conclusion: The considerably high acceptance and the preparedness to use the psoriasis CDSS suggests that a TRS appears to be implementable in routine healthcare and may improve clinical care. Main barrier is the additional time demand posed on dermatologists in a busy clinical setting. Therefore, it will be a major challenge to identify a limited set of variables that still allows a valid recommendation with precise prediction of the patient-individual benefits and harms.
- Open Access
- 5 July 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (10) , 2919-2920
Correction to: Incident autoimmune diseases in association with SARS-CoV-2 infection: A matched cohort study
- 5 July 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (10) , 2919-2920
Open AccessCorrection to: Incident autoimmune diseases in association with SARS-CoV-2 infection: A matched cohort study